Withdrawal of approval application and discontinuation of development due to ulipristal-induced liver injury
A specific drug development project that was discontinued after the approval application in Japan was withdrawn in response to severe liver injury associated with ulipristal. A special loss was recognized in connection with this.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.